As public health officials continue to lament a dearth of antibiotics, a new report finds some drug makers are making strides in developing medicines to combat superbugs, but that the pharmaceutical industry, in general, needs to do more.

Overall, more companies are addressing R&D priorities, particularly the development of new antimicrobial drugs, but remain less active in bolstering manufacturing or sufficiently widening access, according to the report from the Access to Medicines Foundation, a non-profit based in the Netherlands, that regularly compiles indices to rank the progress made by drug companies on various matters.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I urge relevant governmental agencies to do more as well.
    1. Incentivize development of new antibiotics — there returns in antibiotics simply aren’t there relative to many other areas. Pharma companies are for-profit entities. We shame if they aren’t producing, shame if they price to provide a worthy return on investment (especially when new antibiotics are unlikely to be widely used until well after they lose patent). We act like they are public health entities, but that’s just not the case
    2. Crack down on agricultural use of antibiotics to stimulate growth and/or prevent illnesses rather than treating
    3. Crack down on prescribing antibiotics for non-bacterial infections

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy